by Eriksen Insurance | Jun 12, 2026 | Uncategorized
Novo Nordisk launched an oral version of its weight loss drug Wegovy on January 5, 2026, and the numbers since then have been hard to ignore. In roughly five months, the pill crossed 3 million prescriptions in the U.S., a pace the company describes as one of the...
by Eriksen Insurance | Jun 1, 2026 | Uncategorized
Karleigh McClain did everything she thought she was supposed to do. She researched her options, signed up with a reputable-seeming telehealth company, met virtually with a provider, and started a weight loss medication that had helped her lose 50 pounds just a few...
by Eriksen Insurance | May 15, 2026 | Uncategorized
For the first time in its history, Medicare is preparing to cover weight loss drugs at scale. Beginning July 1, 2026, the new Medicare GLP-1 Bridge will give eligible Part D beneficiaries access to medications like Wegovy, Zepbound, and the newly approved Foundayo for...
by Eriksen Insurance | May 15, 2026 | Uncategorized
The Centers for Medicare and Medicaid Services refreshed its Overall Hospital Quality Star Rating this week, and the new numbers tell a familiar story. Most American hospitals are clustered in the middle of the distribution, with a small group of standouts at the top,...
by Eriksen Insurance | May 4, 2026 | Uncategorized
Medicare is about to do something it has never done before: cover prescription weight loss drugs. Starting July 1, 2026, eligible Medicare beneficiaries can get Wegovy, Zepbound, or Foundayo for just $50 a month through a new program called the Medicare GLP-1 Bridge....
by Eriksen Insurance | Apr 22, 2026 | Uncategorized
Most people already know health care is expensive, but the numbers tell a stark story. About 6 in 10 adults say they are very or somewhat worried about affording health care for themselves and their families, making it the top financial concern, ahead of food and...
